This week's news includes Adaptive Biotechnologies, Thermo Fisher Scientific, TATAA Biocenter, and New England Biolabs.
The new partnership will support the analysis of glycans in 30,000 human samples by the end of 2021.
New England Biolabs is using Avacta's affimers with a development-stage research and diagnostic assay that could launch as early as next year.
The partnership will allow customers using NEBNext Direct target enrichment products to analyze data with the Bluebee platform.
The two companies will work to characterize new Cas nucleases, and NEB will then manufacture and commercially distribute the nucleases globally.
The services will couple NEB's reagents and expertise in enzyme development and manufacturing with TTP's Desktop Biology product development and engineering know-how.
Researchers outlined the "nicking enzyme-assisted sequencing" (NicE-seq) protocol and presented results from proof-of-principal open chromatin profiling experiments.
In Science this week: intellectual property landscape of CRISPR genome editing, and more.
The team found that DNA damage affects a variety of samples and may lead to erroneous low-frequency variant calls unless stringent filtering is applied or the damage is repaired prior to sequencing.
The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.
The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.
New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.
In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.